Anticancer agent 164

• Description:

  CML-IN-1 (compound 7) is a potent anticancer agent. CML-IN-1 displays very good induced-apoptosis effect for human chronic myeloid leukemia (CML) cell line K562. CML-IN-1 exerts its effect via a significantly reduced protein phosphorylation of PI3K/Akt signal pathway. CML-IN-1 (compound 4) also inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer[1][2].

• UNSPSC:

  12352005

• Target:

  Apoptosis; MEK; PI3K

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; MAPK/ERK Pathway; PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/anticancer-agent-164.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NC1=CC=C(C(F)(F)F)C=C1)NC2=NN=C(SC3=NC=NC(NCCCN4CCOCC4)=C3)S2

• Molecular Formula:

  C21H23F3N8O2S2

• Molecular Weight:

  540.58

• References & Citations:

  [1]Li W, et al. Design and synthesis of novel 1-phenyl-3- (5- (pyrimidin-4-ylthio) -1,3,4-thiadiazol- 2-yl) urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway. Bioorg Med Chem Lett. 2019 Jul 15;29 (14) :1831-1835.|[2]Li W, et al. A novel 4- (1,3,4-thiadiazole-2-ylthio) pyrimidine derivative inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer. Acta Pharm. 2023 Sep 14;73 (3) :489-502.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2235393-30-1